• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

Microsoft AI chief gives it 18 months—for all white-collar work to be automated by AI

2

Former top Russian official admits the country is over Putin and can 'imagine a future without him' — even elites bail as Kremlin seizes their assets 

3

Meet the 20-year-old CEO who launched a company in high school to solve Gen Z's entry-level job crisis

1

Microsoft AI chief gives it 18 months—for all white-collar work to be automated by AI

2

Former top Russian official admits the country is over Putin and can 'imagine a future without him' — even elites bail as Kremlin seizes their assets 

3

Meet the 20-year-old CEO who launched a company in high school to solve Gen Z's entry-level job crisis
HealthOzempic

Ozempic and Wegovy surge to national approval with most U.S. adults considering it ‘a good thing’ to treat obesity

By
The Associated Press
The Associated Press
,
Kenya Hunter
Kenya Hunter
, and
Linley Sanders
Linley Sanders
Down Arrow Button Icon
By
The Associated Press
The Associated Press
,
Kenya Hunter
Kenya Hunter
, and
Linley Sanders
Linley Sanders
Down Arrow Button Icon
January 31, 2025, 2:26 PM ET
Ozempic and Wegovy medications side by side
A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans.Steve Christo-Corbis—Corbis via Getty Images

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health condition tied to weight, but they are not broadly supportive of teens who have obesity using the medications, according to a new poll from The Associated Press-NORC Center for Public Affairs Research.

Recommended Video

When it comes to ages 12 to 18 who are dealing with obesity, Americans are divided: About one-third say the use of weight-loss drugs in this context is a “very” or “somewhat” good thing, a similar share say it’s a bad thing and about 3 in 10 say it isn’t good or bad.

For adults, about half think it’s a good thing, and about 2 in 10 think it’s a bad thing.

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in popularity after the Food and Drug Administration approved them for weight loss in 2021. Now, they’re all over the place — celebrities, TV advertisements, social media, news media, your neighbor.

Doctors and researchers say the injectable drugs are a effective tools when it comes to treating obesity. The American Medical Association has urged health insurance companies to cover the drugs, and the American Academy of Pediatrics has said that doctors should consider giving the medications to kids 12 and older who are struggling with obesity.

The AP-NORC poll results indicate that even as doctors urge the drugs’ use, some Americans continue to have concerns about weight-loss drugs, particularly for teens and people who aren’t struggling with obesity.

How many Americans are obese?

According to the Centers for Disease Control and Prevention, more than 100 million adults in the U.S. are obese — defined as having a body mass index of 30 or higher — and more than 22 million adults are severely obese, with a BMI of 40 or higher.

Obesity is classified as a chronic disease that needs medical attention, because it can result from genetics, environmental factors and socioeconomic factors. Patients who use the drugs as an extra boost to lose weight can face criticism that they’re somehow “cheating,” said Dr. Cate Varney, who treats patients with obesity at UVA Health in Charlottesville, Virginia.

“It’s like telling somebody to nail a nail into a board and then giving one person a hammer and another person, you know, like a chopstick,” Varney said, adding, “we’re leveling the playing field with these medications.”

Anjanette Ewen lost 67 pounds on Mounjaro, and credits that weight loss as the reason she found a cancerous lump on her breast. The 50-year-old from Fort Walton Beach, Florida, who responded to the AP-NORC poll, said she had struggled to lose weight for years because of complications with polycystic ovarian syndrome.

Because of PCOS, which has a common symptom of sudden weight fluctuations, Ewen went from 150 pounds to 220 pounds in eight months.

“I’ve been on a weight loss journey for forever, it seems like, and nothing was working,” she said.

About 20% of children in the U.S. have obesity, according to CDC data. Dr. Gitanjali Srivastava, the medical director of obesity medicine at Vanderbilt University School of Medicine, said obesity is easier to treat in children than in adults.

“The youth actually respond beautifully to these medications,” she said, adding that obesity at a young age increases the chance “of having even severe and more profound obesity as an adult … to the point that you will actually have to have medications and or bariatric surgery as an adult.”

How much does Ozempic cost without insurance?

Without insurance, out-of-pocket costs for the drugs can run hundreds of dollars each time you fill a prescription.

The AP-NORC poll shows about half of Americans “strongly” or “somewhat” favor having the federal programs Medicare and Medicaid cover weight-loss drugs for people who have obesity, while about 2 in 10 are opposed the idea and about one-quarter have a neutral view.

So far, Medicare, the health insurance program for 66 million Americans 65 and older, doesn’t cover the drugs for obesity. Coverage varies under Medicaid, which provides health insurance for low-income Americans.

Some large companies with 500 employees or more and some Medicaid programs are adding coverage. But many other employers and health insurers are scaling back, with some citing treatment costs.

Can you use Ozempic if you’re not obese?

You can’t get weight-loss drugs without a prescription, though there are off-market compounds that people can purchase.

The AP-NORC poll showed that about 6 in 10 Americans believe it is a “very” or “somewhat” bad thing for adults to take GLP-1s for weight loss if they’re not obese, and that increases to about 7 in 10 for teens in the same situation.

Younger adults, though, are a little more open to the use of GLP-1s for teens who aren’t dealing with obesity. About 8 in 10 Americans above the age of 45 believe it’s a “bad idea” for teenagers who want to lose weight by using the drugs but aren’t obese, but about two-thirds of American adults under the age of 45 hold the same opinion.

___

AP Health Writer Tom Murphy in Indianapolis contributed to this report. Hunter reported from Atlanta. Sanders reported from Washington.

___

The AP-NORC poll of 1,147 adults was conducted Jan. 9-13, using a sample drawn from NORC’s probability-based AmeriSpeak Panel, which is designed to be representative of the U.S. population. The margin of sampling error for adults overall is plus or minus 3.9 percentage points.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

The Fortune 500 Innovation Forum will convene Fortune 500 executives, U.S. policy officials, top founders, and thought leaders to help define what’s next for the American economy, Nov. 16-17 in Detroit. Apply here.
About the Authors
By The Associated Press
See full bioRight Arrow Button Icon
By Kenya Hunter
See full bioRight Arrow Button Icon
By Linley Sanders
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in Health

hoeg
HealthFDA
RFK ally confirms she was fired by FDA: ‘I learned so much and leave with no regrets’
By Matthew Perrone and The Associated PressMay 16, 2026
16 hours ago
lawyer
CommentaryLaw
Would you hire the lawyer who just got sanctioned for using AI?
By Alexandra SmythMay 16, 2026
20 hours ago
lori
Commentarymental health
I run Valvoline Instant Oil Change and work with young people every day. They’re in crisis—and we all have to try to help
By Lori FleesMay 15, 2026
2 days ago
Claude is telling users to go to sleep mid-session and nobody, including Anthropic, seems to fully understand why it keeps doing it
AITech
Claude is telling users to go to sleep mid-session and nobody, including Anthropic, seems to fully understand why it keeps doing it
By Marco Quiroz-GutierrezMay 14, 2026
2 days ago
Nonprofit CEOs say Trump’s economy is driving surging demand—and they’re pushed to the brink
Future of Workphilanthropy
Nonprofit CEOs say Trump’s economy is driving surging demand—and they’re pushed to the brink
By Sydney LakeMay 14, 2026
3 days ago
Transparent Labs Protein Powder Review (2026): Nutrition Expert Approved
HealthDietary Supplements
Transparent Labs Protein Powder Review (2026): Nutrition Expert Approved
By Emily PharesMay 14, 2026
3 days ago

Most Popular

Microsoft AI chief gives it 18 months—for all white-collar work to be automated by AI
AI
Microsoft AI chief gives it 18 months—for all white-collar work to be automated by AI
By Jake AngeloMay 16, 2026
18 hours ago
Former top Russian official admits the country is over Putin and can 'imagine a future without him' — even elites bail as Kremlin seizes their assets 
Politics
Former top Russian official admits the country is over Putin and can 'imagine a future without him' — even elites bail as Kremlin seizes their assets 
By Jason MaMay 16, 2026
9 hours ago
Meet the 20-year-old CEO who launched a company in high school to solve Gen Z's entry-level job crisis
Future of Work
Meet the 20-year-old CEO who launched a company in high school to solve Gen Z's entry-level job crisis
By Jake AngeloMay 16, 2026
22 hours ago
The Bezos family just donated $100 million to help achieve one of Mayor Zohran Mamdani’s top campaign promises
Politics
The Bezos family just donated $100 million to help achieve one of Mayor Zohran Mamdani’s top campaign promises
By Jake AngeloMay 12, 2026
4 days ago
Despite having a $165 million net worth, Scarlett Johansson says work-life balance doesn’t exist—and the first step to success is admitting that
Success
Despite having a $165 million net worth, Scarlett Johansson says work-life balance doesn’t exist—and the first step to success is admitting that
By Preston ForeMay 13, 2026
4 days ago
‘You’re not a hero, you’re a liability’: Shark Tank’s Kevin O’Leary warns Gen Z founders to stop glorifying hustle culture
Future of Work
‘You’re not a hero, you’re a liability’: Shark Tank’s Kevin O’Leary warns Gen Z founders to stop glorifying hustle culture
By Jacqueline MunisMay 16, 2026
18 hours ago